Literature DB >> 28385673

Advancements in the use of gene therapy for cardiac arrhythmia.

Nathaniel P Murphy1, Ellen R Lubbers1, Peter J Mohler2.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28385673      PMCID： PMC5942548          DOI： 10.1016/j.hrthm.2017.03.041

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN： 1547-5271            Impact factor:   6.343


× No keyword cloud information.
  17 in total

1.  Flecainide monotherapy is an option for selected patients with catecholaminergic polymorphic ventricular tachycardia intolerant of β-blockade.

Authors:  Gareth J Padfield; Leenah AlAhmari; Krystien V V Lieve; Tasneem AlAhmari; Thomas M Roston; Arthur A Wilde; Andrew D Krahn; Shubhayan Sanatani
Journal:  Heart Rhythm       Date:  2015-09-28       Impact factor: 6.343

2.  Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia.

Authors:  Christian van der Werf; Prince J Kannankeril; Frederic Sacher; Andrew D Krahn; Sami Viskin; Antoine Leenhardt; Wataru Shimizu; Naokata Sumitomo; Frank A Fish; Zahurul A Bhuiyan; Albert R Willems; Maurits J van der Veen; Hiroshi Watanabe; Julien Laborderie; Michel Haïssaguerre; Björn C Knollmann; Arthur A M Wilde
Journal:  J Am Coll Cardiol       Date:  2011-05-31       Impact factor: 24.094

Review 3.  Gene therapy to treat cardiac arrhythmias.

Authors:  Rossana Bongianino; Silvia G Priori
Journal:  Nat Rev Cardiol       Date:  2015-04-28       Impact factor: 32.419

4.  2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC).

Authors:  Silvia G Priori; Carina Blomström-Lundqvist; Andrea Mazzanti; Nico Blom; Martin Borggrefe; John Camm; Perry Mark Elliott; Donna Fitzsimons; Robert Hatala; Gerhard Hindricks; Paulus Kirchhof; Keld Kjeldsen; Karl-Heinz Kuck; Antonio Hernandez-Madrid; Nikolaos Nikolaou; Tone M Norekvål; Christian Spaulding; Dirk J Van Veldhuisen
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983

Review 5.  Catecholaminergic Polymorphic Ventricular Tachycardia.

Authors:  Krystien V Lieve; Christian van der Werf; Arthur A Wilde
Journal:  Circ J       Date:  2016-05-13       Impact factor: 2.993

Review 6.  Clinical Challenges in Catecholaminergic Polymorphic Ventricular Tachycardia.

Authors:  Jacopo F Imberti; Katherine Underwood; Andrea Mazzanti; Silvia G Priori
Journal:  Heart Lung Circ       Date:  2016-02-16       Impact factor: 2.975

7.  Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans.

Authors:  Hiroshi Watanabe; Nagesh Chopra; Derek Laver; Hyun Seok Hwang; Sean S Davies; Daniel E Roach; Henry J Duff; Dan M Roden; Arthur A M Wilde; Björn C Knollmann
Journal:  Nat Med       Date:  2009-03-29       Impact factor: 53.440

8.  Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients.

Authors:  A Leenhardt; V Lucet; I Denjoy; F Grau; D D Ngoc; P Coumel
Journal:  Circulation       Date:  1995-03-01       Impact factor: 29.690

9.  Viral gene transfer rescues arrhythmogenic phenotype and ultrastructural abnormalities in adult calsequestrin-null mice with inherited arrhythmias.

Authors:  Marco Denegri; José Everardo Avelino-Cruz; Simona Boncompagni; Stefano Andrea De Simone; Alberto Auricchio; Laura Villani; Pompeo Volpe; Feliciano Protasi; Carlo Napolitano; Silvia Giuliana Priori
Journal:  Circ Res       Date:  2012-01-31       Impact factor: 17.367

10.  Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia.

Authors:  Silvia G Priori; Carlo Napolitano; Mirella Memmi; Barbara Colombi; Fabrizio Drago; Maurizio Gasparini; Luciano DeSimone; Fernando Coltorti; Raffaella Bloise; Roberto Keegan; Fernando E S Cruz Filho; Gabriele Vignati; Abraham Benatar; Angelica DeLogu
Journal:  Circulation       Date:  2002-07-02       Impact factor: 29.690
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.